Long Non-Coding RNAs Associated with Breast Cancer Cell Apoptosis Following Resveratrol Treatment: An In Silico Analysis

Document Type : Original Article

Authors

1 Department of Food Science, University of Otago, Dunedin, New Zealand

2 Department of Plant Protection, Nuclear Agriculture Research School, Nuclear Science and Technology Research Institute (NSTRI), Karaj, Iran

3 Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran

4 Department of Microbiology, Faculty of Basic Sciences, Shahroud Branch, Islamic Azad University, Shahroud, Iran

Abstract

Phytochemicals such as resveratrol accomplish their pleiotropic anti-tumor activities by modulating the expression of non-coding RNAs. This study examined the role of resveratrol in modulating long non-coding RNAs (lncRNAs) for apoptosis of breast cancer cells. An RNA-Seq dataset available in the NCBI, in which resveratrol-induced apoptosis in a breast cancer cell line (MDA-MB-231), was analyzed to explore the differential expression of lncRNAs. In the resveratrol-treated group, 335 lncRNAs with differential expression were identified between the control and treatment groups, of which 167 and 168 lncRNAs were upregulated and downregulated, respectively. Among the upregulated putative lncRNAs, the maximum fold change was ~34, belonging to LINC00261. Among the downregulated putative lncRNAs, the maximum fold change was -191.3, which belongs to DLEU2L. The main upregulated novel lncRNAs, with a ~50-fold increase in the content, belonged to lnc-KLF-1. Our study predicted overexpression of novel lnc-KLF-1 and LINC00261 as a signature of the response of breast cancer cells to resveratrol treatment. Furthermore, a network of interactions between the lncRNAs and miRNAs was constructed, and key-lncRNA in this network was highlighted. Our study's comparative analysis of the lncRNA transcriptional landscape discovered several novel lncRNA candidates that may regulate the response of breast cancer cells to resveratrol treatment. This may pave the way for developing new molecular biomarkers with diagnostic, prognostic, and potential therapeutic values.

Keywords

References

  1. Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573. https://doi.org/10.3390/ijms20225573
  2. Dragomir MP, Knutsen E, Calin GA. SnapShot: unconventional miRNA functions. Cell. 2018;174(4):1038. https://doi.org/10.1016/j.cell.2018.07.040
  3. López-Urrutia E, Bustamante Montes LP, Ladrón de Guevara Cervantes D, Pérez-Plasencia C, Campos-Parra AD. Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. Front Oncol. 2019;9:669. https://doi.org/10.3389/fonc.2019.00669
  4. Aravindhan S, Younus LA, Hadi Lafta M, Markov A, Ivanovna Enina Y, Yushchenkо NA, et al. P53 long noncoding RNA regulatory network in cancer development. Cell Biol Int. 2021;45(8):1583–98. https://doi.org/10.1002/cbin.11600
  5. Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96–118. https://doi.org/10.1038/s41580-020-00315-9
  6. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660
  7. Cao J, Zhang M, Wang B, Zhang L, Zhou F, Fang M. Chemoresistance and metastasis in breast cancer molecular mechanisms and novel clinical strategies. Front Oncol. 2021;11:658552. https://doi.org/10.3389/fonc.2021.658552
  8. Malayeri MRM, Dadkhah A, Fatemi F, Dini S, Torabi F, Tavajjoh MM, et al. Chemotherapeutic effect of Berberis integerrima hydroalcoholic extract on colon cancer development in the 1,2-dimethyl hydrazine rat model. Zeitschrift für Naturforsch C. 2016;71(7–8):225–32. https://doi.org/10.1515/znc-2015-0117
  9. Dini S, Singh S, Fatemi F. The Hepatoprotective Possessions of Specific Iranian Medicinal Plants. J Food Biochem. 2024;2024:8783113. https://doi.org/10.1155/2024/8783113
  10. Siddiqu SA, Dini S, Esmaeili Y, Roshanak S, Redha AA, Wani SA. Uses of carotenoid-rich ingredients to design functional foods: a review. J Food Bioact. 2023;21. https://doi.org/10.31665/JFB.2023.18334
  11. Rasooli A, Fatemi F, Hajihosseini R, Vaziri A, Akbarzadeh K, Mohammadi Malayeri MR, et al. Synergistic effects of deuterium depleted water and Mentha longifolia L. essential oils on sepsis-induced liver injuries through regulation of cyclooxygenase-2. Pharm Biol. 2019;57(1):125–32. https://doi.org/10.1080/13880209.2018.1563622
  12. Ayaz M, Nawaz A, Ahmad S, Mosa OF, Eisa Hamdoon AA, Khalifa MA, et al. Underlying anticancer mechanisms and synergistic combinations of phytochemicals with cancer chemotherapeutics: potential benefits and risks. J Food Qual. 2022;2022:1189034. https://doi.org/10.1155/2022/1189034
  13. Dini S, Chen Q, Fatemi F, Asri Y. Phytochemical and biological activities of some Iranian medicinal plants. Pharm Biol. 2022;60(1):664–89. https://doi.org/10.1080/13880209.2022.2046112
  14. Ren B, Kwah MXY, Liu C, Ma Z, Shanmugam MK, Ding L, et al. Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Lett. 2021;515:63–72. https://doi.org/10.1016/j.canlet.2021.05.001
  15. Cesmeli S, Goker Bagca B, Caglar HO, Ozates NP, Gunduz C, Biray Avci C. Combination of resveratrol and BIBR1532 inhibits proliferation of colon cancer cells by repressing expression of LncRNAs. Med Oncol. 2022;39(1):1–10. https://doi.org/10.1007/s12032-021-01611-w
  16. Zhou Y, Zhang J, Li W, Zhang D, Wang Z, Zhai Y, et al. Integrative investigation of the TF–miRNA coregulatory network involved in the inhibition of breast cancer cell proliferation by resveratrol. FEBS Open Bio. 2022;12(2):379. https://doi.org/10.1002/2211-5463.13344
  17. Liang ZJ, Wan Y, Zhu DD, Wang MX, Jiang HM, Huang DL, et al. Resveratrol mediates the apoptosis of triple negative breast cancer cells by reducing POLD1 expression. Front Oncol. 2021;11:569295. https://doi.org/10.3389/fonc.2021.569295
  18. Giordo R, Wehbe Z, Posadino AM, Erre GL, Eid AH, Mangoni AA, et al. Disease-associated regulation of non-coding RNAs by resveratrol: molecular insights and therapeutic applications. Front Cell Dev Biol. 2022;10:894305. https://doi.org/10.3389/fcell.2022.894305
  19. Shaikh M, Doshi G. Unraveling non-coding RNAs in breast cancer: mechanistic insights and therapeutic potential. Med Oncol. 2024;42(1):37. https://doi.org/10.1007/s12032-024-02589-x
  20. Kong L, Zhang Y, Ye ZQ, Liu XQ, Zhao SQ, Wei L, et al. CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic Acids Res. 2007;35(suppl_2):W345–9. https://doi.org/10.1093/nar/gkm391
  21. Zou JY, Chen QL, Luo XC, Damdinjav D, Abdelmohsen UR, Li HY, et al. Natural products reverse cancer multidrug resistance. Front Pharmacol. 2024;15:1348076. https://doi.org/10.3389/fphar.2024.1348076
  22. Keshavarzmotamed A, Mousavi V, Masihipour N, Rahmati A, Dehmordi RM, Ghezelbash B, et al. Regulating miRNAs expression by resveratrol: novel insights based on molecular mechanism and strategies for cancer therapy. Curr Mol Pharmacol. 2024;17(1):E18761429249717. https://doi.org/10.2174/0118761429249717230920113227
  23. Mozafaryan MJ, Rezaei P, Masoudpoor F, Bahri A, Samini M, Farkhondeh T, et al. Resveratrol in the Treatment of Gynecological Cancer: Mechanisms and Therapeutic Potential. Curr Med Chem. 2025. https://doi.org/10.2174/0109298673290941240430171146
  24. Doghish AS, El-Dakroury WA, Abulsoud AI, Abdelmaksoud NM, Aly SH, Elbadry AMM, et al. Natural compounds as regulators of miRNAs: exploring a new avenue for treating brain cancer. Naunyn Schmiedebergs Arch Pharmacol. 2025;1–18. https://doi.org/10.1007/s10142-025-01547-8
  25. Otsuka K, Yamamoto Y, Ochiya T. Regulatory role of resveratrol, a microRNA-controlling compound, in HNRNPA1 expression, which is associated with poor prognosis in breast cancer. Oncotarget. 2018;9(37):24718. https://doi.org/10.18632/oncotarget.25339
  26. Nemeth K, Bayraktar R, Ferracin M, Calin GA. Non-coding RNAs in disease: from mechanisms to therapeutics. Nat Rev Genet. 2024;25(3):211–32. https://doi.org/10.1038/s41576-023-00662-1
  27. Chen LL, Kim VN. Small and long non-coding RNAs: Past, present, and future. Cell. 2024;187(23):6451–85. https://doi.org/10.1016/j.cell.2024.10.024
  28. Zhang Y, Zhan L, Jiang X, Tang X. Comprehensive review for non-coding RNAs: From mechanisms to therapeutic applications. Biochem Pharmacol. 2024;116218. https://doi.org/10.1016/j.bcp.2024.116218
  29. Pokorná M, Černá M, Boussios S, Ovsepian SV, O’Leary VB. lncRNA biomarkers of glioblastoma multiforme. Biomedicines. 2024;12(5):932. https://doi.org/10.3390/biomedicines12050932
  30. Ferrando L, Cirmena G, Garuti A, Scabini S, Grillo F, Mastracci L, et al. Development of a long non-coding RNA signature for prediction of response to neoadjuvant chemoradiotherapy in locally advanced rectal adenocarcinoma. PLoS One. 2020;15(2):e0226595. https://doi.org/10.1371/journal.pone.0226595
  31. Guo G, Dai S, Chen Q. Long noncoding RNA LINC00261 reduces proliferation and migration of breast cancer cells via the NME1-EMT pathway. Cancer Manag Res. 2020;12:3081. https://doi.org/10.2147/CMAR.S237197
  32. Huna A, Nawrocki-Raby B, Padilla-Benavides T, Gavard J, Coscoy S, Bernard D, et al. Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial–Mesenchymal State in Cancer Cells. Int J Mol Sci. 2021;22(7):3718. https://doi.org/10.3390/ijms22073718
  33. Mertens D, Wolf S, Bullinger L, Ohl S, Schaffner C, Döhner H, et al. BCMSUN, a candidate gene for B‐cell chronic lymphocytic leukemia and mantle‐cell lymphoma, has an independently expressed homolog on 1p22‐p31, BCMSUN‐like. Int J Cancer. 2000;88(5):692–7. https://doi.org/10.1002/1097-0215(20001201)88:5%3C692::AID-IJC2%3E3.0.CO;2-3
  34. Xu W, Wang B, Cai Y, Guo C, Liu K, Yuan C. DLEU2: a meaningful long noncoding RNA in oncogenesis. Curr Pharm Des. 2021;27(20):2337–43. https://doi.org/10.2174/1381612826666201026150857
  35. Shi Y, Zhang D-D, Liu J-B, Yang X-L, Xin R, Jia C-Y, et al. Comprehensive analysis to identify DLEU2L/TAOK1 axis as a prognostic biomarker in hepatocellular carcinoma. Mol Ther Nucleic Acids. 2021;23:702–18. https://doi.org/10.1016/j.omtn.2020.12.016
  36. Nazem H, Javani AF, Fazilati M, Ghaedi K. Long non-coding RNAs including IRF1-AS1, LINC01871, TRG-AS1, and USP30-AS as tumor suppressors in colorectal cancer; in silico analysis. Arch Adv Biosci. 2023;14(1):1–5. https://doi.org/10.22037/aab.v14i1.39529
  37. Huang J, Li J, Li Y, Lu Z, Che Y, Mao S, et al. Interferon-inducible lncRNA IRF1-AS represses esophageal squamous cell carcinoma by promoting interferon response. Cancer Lett. 2019;459:86–99. https://doi.org/10.1016/j.canlet.2019.05.038
Veterinary and Comparative Biomedical Research
Volume 2, Issue 2
December 2025
Pages 1-10

Files

Share

How to cite

Statistics